Clinical Trial: Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis

U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515066) titled 'Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis' on March 26.

Brief Summary: This is a single-center, open-label, dose-escalation clinical study to evaluate the safety and efficacy of nebulized 3D-cultured human placental mesenchymal stem cell-derived extracellular vesicles (hPMSC-EVs) in patients with idiopathic pulmonary fibrosis (IPF).

Eligible participants will be assigned to one of three dose groups (1.0x10⁹, 2.0x10⁹, or 3.0x10⁹ particles per treatment) using a 3+3 design. All participants will rece...